Stay updated with breaking news from Recode Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Avalyn Pharma aims to improve treatment of Idiopathic pulmonary fibrosis with inhalable versions of two older oral drugs and it’s now headed for mid-stage testing backed by a Series C financing. Other recent biotech industry financings raised money for research in cancer, immunology, and rare genetic diseases.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
'Cystic fibrosis has provided a framework for approaching the genetics of lung fibrosis.'
– Former FDA Associate Commissioner of External Affairs brings nearly 20 years of communications, patient advocacy and public affairs experience across government, public and private sectors –MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a clinical-stage genetic medicines company using superior delivery...
MENLO PARK, Calif.--(BUSINESS WIRE)--ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, today announced that Angèle Maki, Ph.D., Senior Vice President, Business Development of ReCode Therapeutics, will present a company overview a...